2-(羟基甲基)-4-苯基-5-(三氟甲基)噻吩 | 256488-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-(羟基甲基)-4-苯基-5-(三氟甲基)噻吩
• 英文名称: 2-hydroxymethyl-4-phenyl-5-trifluoromethylthiophene
• 英文别名: (4-phenyl-5-trifluoromethylthiophen-2-yl)methanol；2-hydroxymethyl-4-phenyl-5-trifluoromethyl-thiophene；4-phenyl-5-trifluoromethylthiophene-2-methanol；(4-Phenyl-5-(trifluoromethyl)thiophen-2-yl)methanol；[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]methanol
• CAS: 256488-46-7
• 化学式: C₁₂H₉F₃OS
• 分子量: 258.264
• InChiKey: AUJMSBKJCOVWFV-UHFFFAOYSA-N

物化性质

• 沸点：
  304.5±42.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(羟基甲基)-4-苯基-5-(三氟甲基)噻吩 在 4-二甲氨基吡啶 、 四溴化碳 、 potassium carbonate 、 三苯基膦 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 生成 2-Oxo-5-[4-(4-phenyl-5-trifluoromethyl-thiophen-2-ylmethoxy)-phenyl]-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester
  参考文献：
  名称：

  2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors

  摘要：

  A series of 2-aryl(pyrrolidin-4-yl)acetic acids were synthesized and their biological activities were evaluated as agonists of SIP receptors. These analogs were able to induce lowering of lymphocyte counts in the peripheral blood of mice and were found to have good overall pharmacokinetic properties in rat. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.090
• 作为产物：
  描述：

  1,1,1-三氟-3-苯基丙酮 在 sodium hydroxide 、 硼烷四氢呋喃络合物 、 sodium hydride 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 43.5h， 生成 2-(羟基甲基)-4-苯基-5-(三氟甲基)噻吩
  参考文献：
  名称：

  A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists

  摘要：

  Moderately potent, selective SIP, receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

  DOI：

  10.1021/jm0492507

文献信息

• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• [EN] BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES BICYCLIQUES DE 1-PHOSPHATE DE SPHINGOSINE
  申请人：UNIV VIRGINIA

  公开号：WO2009023854A1

  公开（公告）日：2009-02-19

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors. Formula (I):

  提供具有在一个或多个SlP受体上激动剂活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后可以在SlP受体上表现为激动剂。公式（I）：
• [EN] CYANOTRIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS CYANOTRIAZOLE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2015008872A1

  公开（公告）日：2015-01-22

  This invention relates to a cyanotriazole compound represented by the formula (1):, wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖，副作用较少，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病，糖耐量受损，胰岛素抵抗，糖尿病并发症，肥胖，血脂异常，肝脂肪变性，动脉粥样硬化和/或心血管疾病，以及那些受益于刺激能量消耗的疾病或疾病。
• [EN] EDG RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR EDG
  申请人：MERCK & CO INC

  公开号：WO2003062252A1

  公开（公告）日：2003-07-31

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖式I的化合物：以及其药学上可接受的盐和水合物。该化合物可用于治疗免疫介导的疾病和病状，例如骨髓、器官和组织移植排斥。还包括制药组合物和使用方法。
• 1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
  申请人：Doherty A. George

  公开号：US20060161005A1

  公开（公告）日：2006-07-20

  The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖以下式子(I)的化合物：以及其药学上可接受的盐和水合物。这些化合物可用于治疗免疫介导的疾病和病况，如骨髓、器官和组织移植排斥。还包括药物组成物和使用方法。